BioSpace News Archive

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 fourth quarter ended September 30, 2018, and provided its financial outlook for fiscal 2019.

China Jo-Jo Drugstores, Inc. today announced that Mr. Wei Hu was nominated and approved by the Company’s Board of Directors to serve as the Company’s Chief Operating Officer effective November 7, 2018.

Therapeutic Research Center (TRC® Healthcare, or TRC),, announced today an agreement that enables UPhA to offer its individual members and Utah-based retail pharmacies employer-based training via subscription to Pharmacy Technicians University,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

Pliant Therapeutics, Inc, today announced company scientists and research collaborators will present in vivo data highlighting Pliant’s clinical product candidates in two posters at The Liver Meeting® 2018

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced advancements in the company’s oncology program.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented updated results from the ongoing Phase 1/2 open-label extension (OLE) study of givosiran, an investigational RNAi therapeutic, targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP).

Halo Labs Inc. is pleased to report dispensary sales of approximately US$1.23 million for October 2018. This is an increase of approximately US$353,000 over September 2018. Approximately US$245,000 of the dispensary sales in October was derived from the Company’s first full month of sales to dispensaries in Nevada.

Dicerna Pharmaceuticals, Inc. will host an R&D Day today in New York City to discuss its pipeline of GalXC™-based RNAi therapeutic candidates.

GS-9674 Granted Orphan Drug Designation by the U.S. Food and Drug Administration